BELAGENPUMATUCEL-L (SK-LU-1)
Lung Neoplasm
NovaRx CorporationCell therapyPhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
52 Active assets in the Lung Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Nanfang Hospital, Southern Medical University | Phase 4 | BB |
Nivolumab Hospital Israelita Albert Einstein | Phase 2 | BB |
Icotinib Fuda Cancer Hospital, Guangzhou | Phase 4 | BB |
Cyclophosphamide Pfizer | Phase 3 | BB |
Rivoceranib Fuzhou General Hospital | Phase 3 | BB |
View all 50 →
Same molecule, other indications
BELAGENPUMATUCEL-L (SK-LU-1) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →